Previous 10 | Next 10 |
2024-06-21 09:44:16 ET More on Hims & Hers Health Hims & Hers: The Undervalued Gem Poised For Growth Hims & Hers: Compounded Semaglutide Boost Unlikely To Last - Moderate Risks Ahead Hims & Hers: Ready For Takeoff Hims & Hers cut to Neutra...
2024-06-21 08:30:00 ET Ozempic has become the big name associated with weight loss. Although there are other competing drugs which could take market share from it in the future, the diabetes treatment has become well known on social media for its ability to help people lose weight. And th...
2024-06-21 08:20:43 ET More on Zealand Pharma Zealand Pharma A/S (ZLDPF) Q1 2024 Earnings Call Transcript Zealand, Boehringer liver disease drug survodutide shows fibrosis improvement Zealand Pharma releases top-line phase 2 results on weight loss asset dapiglutide ...
2024-06-21 06:56:18 ET Summary Qualcomm stock dips after reports of compatibility issues with Samsung's new laptop. Canada planning tariffs on Chinese EV imports, following U.S. and EU actions. WHO warns of fake versions of Novo Nordisk's diabetes medication, Ozempic. ...
2024-06-20 15:09:50 ET More on Novo Nordisk Novo Nordisk: Leading The Fight Against Diabetes And Obesity Novo Nordisk: The Market Is Right, Don't Fight Against It Novo Nordisk: Not The Best Investment Right Now, But A Great Case Study Novo reports new fire at...
2024-06-20 09:02:55 ET More on Eli Lilly Eli Lilly: The Party Is Probably Nearing The End Eli Lilly And Alzheimer's Disease: The Paucity Of Progress Eli Lilly: The Road To Approval Of Donanemab Is Open Eli Lilly oral weight-loss candidate orforglipron is pote...
2024-06-20 07:35:13 ET More on Evotec SE Evotec SE (EVO) Q1 2024 Earnings Call Transcript Evotec SE 2024 Q1 - Results - Earnings Call Presentation Evotec SE (EVO) Q4 2023 Earnings Call Transcript Evotec to exit gene therapy business, close Austria site ...
2024-06-18 13:49:28 ET More on Eli Lilly Eli Lilly And Alzheimer's Disease: The Paucity Of Progress Eli Lilly: The Road To Approval Of Donanemab Is Open Eli Lilly and Company (LLY) Goldman Sachs 45th Annual Global Healthcare Conference Eli Lilly’s oral...
2024-06-18 13:30:13 ET Eli Lilly’s ( NYSE: LLY ) success with a newer class of diabetes and weight-loss drugs has the potential to be repeated with other products in its research pipeline, healthcare analysts said Tuesday at the Seeking Alpha Investing Summit in New York.... ...
2024-06-18 12:54:18 ET More on Omega Therapeutics Omega Therapeutics And Novo Nordisk Collaboration: A Cautious 'Buy' Seeking Alpha’s Quant Rating on Omega Therapeutics Historical earnings data for Omega Therapeutics Financial information for Omega The...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 05:48:00 ET Novo Nordisk (NYSE: NVO) is riding the Ozempic/Wegovy train straight to the bank. Eli Lilly (NYSE: LLY) is doing the same with Mounjaro and Zepbound. Both big drugmakers have multibillion-dollar obesity drug franchises that continue to grow rapidly. Sh...
2024-07-17 13:21:54 ET Shares of Swiss pharmaceuticals company Roche Holding (OTC: RHHBY) soared 7% through 11:55 a.m. ET Wednesday on positive data from phase 1 clinical trials of its new weight loss drug CT-996. But good news for Roche is bad news for the companies that no...
2024-07-14 05:20:00 ET Two pharma juggernauts, Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) , are picking up speed in their preparations for an epic battle to control the market for weight loss drugs. The prize for the victor will be a larger market share of what may b...